

## Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the approximate overall response rate observed with odronextamab in a Phase II trial for patients with heavily pretreated relapsed/refractory (R/R) follicular lymphoma (FL)?**
  - a. 25%
  - b. 50%
  - c. 70%
  - d. Higher than 80%**
- 2. Which of the following statements best describes observations of cytokine release syndrome with odronextamab in a Phase II trial for patients with heavily pretreated R/R FL?**
  - a. Events were mostly Grade 3 and generally occurred in cycle 3
  - b. Events were mostly Grade 3 and generally occurred in cycle 1 step-up
  - c. Events were mostly Grade 1 and generally occurred in cycle 3
  - d. Events were mostly Grade 1 and generally occurred in cycle 1 step-up**
- 3. Glofitamab has demonstrated clinically meaningful antitumor activity in patients with heavily pretreated R/R FL when administered ...**
  - a. As monotherapy
  - b. In combination with obinutuzumab
  - c. Both a and b**
  - d. Glofitamab has not demonstrated activity in FL
- 4. The Phase I NP39488 study demonstrated preliminary efficacy in patients with R/R diffuse large B-cell lymphoma with the combination of polatuzumab vedotin and which agent?**
  - a. Epcoritamab
  - b. Glofitamab**
  - c. Mosunetuzumab
  - d. Odronextamab
- 5. The ongoing Phase III Celestimo trial is comparing which of the following bispecific antibodies in combination with lenalidomide to R<sup>2</sup> (lenalidomide/rituximab) for patients with R/R FL?**
  - a. Glofitamab
  - b. Epcoritamab
  - c. Mosunetuzumab**
  - d. Odronextamab